European prosecutors keep questions open in vaccine probe

European prosecutors are still pursuing questions regarding European Commission President Ursula von der Leyen's handling of coronavirus vaccine deals. The inquiry, run by the European Public Prosecutor's Office (EPPO), focuses on the Commission chief's direct negotiations with Pfizer chief executive Albert Bourla during the pandemic procurement drive. Despite sustained interest across the European quarter, investigators have shown little demonstrable progress in moving the sensitive file forward.

At stake is the transparency of how the European Union's executive negotiates massive multi-billion-euro purchasing contracts on behalf of its member states. The EPPO is the independent judicial body set up to investigate and prosecute fraud, corruption, and financial mismanagement affecting the EU budget. When the office opens an inquiry reaching the very top of the Berlaymont, it tests whether the bloc's legal accountability mechanisms can scrutinise senior political leadership with the same vigour applied to lower-level financial discrepancies.

Inside the Brussels machinery, the episode colloquially known as Pfizergate has long occupied a strange diplomatic space: continuously discussed in corridor chatter, yet moving at the deliberate, opaque pace characteristic of high-stakes cross-border prosecutions. The Commission has historically guarded its executive communications closely, treating procedural discretion as standard operating procedure. For prosecutors, questioning the head of the EU executive remains one of the most politically sensitive exercises possible under EU treaties, where any misstep risks institutional deadlock.

The European Public Prosecutor's Office has not announced a formal timeline or procedural conclusion for its inquiries. As long as prosecutors hold open questions, the probe remains an unresolved institutional shadow over the Commission leadership, leaving officials to wait for investigators to either press ahead or quietly close the dossier.